XML 74 R4.htm IDEA: XBRL DOCUMENT v2.4.0.8
Consolidated Statements of Comprehensive Income (USD $)
In Thousands, except Per Share data, unless otherwise specified
 12 Months Ended
Jun. 30, 2014
Jun. 30, 2013
Jun. 30, 2012
Molecular diagnostic testing $ 748,198 $ 582,392 $ 472,390
Pharmaceutical and clinical services 30,018 30,773 23,615
Total revenue 778,216 613,165 496,005
Costs and expenses:      
Cost of molecular diagnostic testing 96,140 64,376 51,452
Cost of pharmaceutical and clinical services 13,061 15,242 13,207
Research and development expense 67,476 53,706 42,645
Selling, general, and administrative expense 327,097 251,839 208,383
Total costs and expenses 503,774 385,163 315,687
Operating income 274,442 228,002 180,318
Other income (expense):      
Interest income 5,397 5,497 4,629
Other (1,974) (223) (407)
Total other income (expense): 3,423 5,274 4,222
Income before income taxes 277,865 233,276 184,540
Income tax provision 101,640 86,137 72,389
Net income 176,225 147,139 112,151
Earnings per share:      
Basic $ 2.33 $ 1.82 $ 1.33
Diluted $ 2.25 $ 1.77 $ 1.30
Weighted average shares outstanding:      
Basic 75,728 80,948 84,608
Diluted 78,182 83,327 86,465
Net income 176,225 147,139 112,151
Comprehensive income:      
Unrealized gain (loss) on available-for-sale securities, net of tax 610 (257) (135)
Change in foreign currency translation adjustment, net of tax (1,701) (5) (178)
Comprehensive income $ 175,134 $ 146,877 $ 111,838